Medicinal cannabis ‘worth trialling for chronic pain’
An international panel suggests there is a role for the medication when other interventions fail
Evidence supports doctors offering a trial of non-inhaled medicinal cannabis or cannabinoids for the treatment of chronic pain if standard care proves inadequate, according to new guidance.
Developed by a panel of international experts, including GPs, the ‘weak recommendation’ applies to all patients living with moderate to severe chronic pain, including cancer pain, neuropathic pain, nociceptive pain and nociplastic pain.
